Sigma Planning Corp Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Sigma Planning Corp grew its position in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 5.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,117 shares of the company’s stock after purchasing an additional 773 shares during the quarter. Sigma Planning Corp’s holdings in AstraZeneca were worth $933,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. Capital International Investors grew its holdings in shares of AstraZeneca by 4.5% during the first quarter. Capital International Investors now owns 36,993,664 shares of the company’s stock valued at $2,458,428,000 after buying an additional 1,604,875 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of AstraZeneca by 3.6% during the first quarter. Fisher Asset Management LLC now owns 20,842,845 shares of the company’s stock valued at $1,382,714,000 after buying an additional 732,959 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of AstraZeneca by 5.3% during the first quarter. Bank of America Corp DE now owns 11,169,891 shares of the company’s stock valued at $741,010,000 after buying an additional 560,069 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of AstraZeneca by 16.1% during the second quarter. CIBC Private Wealth Group LLC now owns 10,730,763 shares of the company’s stock valued at $708,981,000 after buying an additional 1,490,165 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of AstraZeneca by 22.0% during the first quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock valued at $495,328,000 after buying an additional 1,343,939 shares during the last quarter. 21.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. Berenberg Bank decreased their target price on shares of AstraZeneca from GBX 120 ($1.41) to GBX 118 ($1.39) in a research report on Wednesday, October 19th. AlphaValue upgraded shares of AstraZeneca to a “reduce” rating in a research report on Monday, August 22nd. TheStreet downgraded shares of AstraZeneca from a “b-” rating to a “c” rating in a research report on Tuesday, August 30th. Morgan Stanley downgraded shares of AstraZeneca from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 7th. Finally, Guggenheim decreased their price objective on shares of AstraZeneca from £120 ($141.01) to £118 ($138.66) in a research report on Tuesday, October 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Hold” and an average target price of $8,264.20.

AstraZeneca Price Performance

Shares of AZN opened at $65.07 on Monday. AstraZeneca PLC has a twelve month low of $52.65 and a twelve month high of $71.70. The firm’s fifty day simple moving average is $57.76 and its 200-day simple moving average is $62.02. The firm has a market capitalization of $201.64 billion, a price-to-earnings ratio of 97.12, a PEG ratio of 1.32 and a beta of 0.50. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.65.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.